Prescient Therapeutics (ASX:PTX) share price leaps 11%, up 50% in a month

Prescient’s shares are on the way up today. Here’s the details.

| More on:
medical research laboratory assistant examines solutions in test tubes

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 index (ASX: XJO) has started the week in the red and is currently down 2% to 7,252.6 points.

Whereas the S&P/ASX 200 Health Care index (XHJ) is also around 1% in the red today, one ASX Healthcare share is outpacing the broad indices.

Clinical research company Prescient Therapeutics Ltd (ASX: PTX)’s shares are now changing hands at 30 cents apiece, which is an 11% gain from the market open today.

Let’s take a closer look at what’s propelling the Prescient share price in today’s session.

What’s up with the Prescient Therapeutics share price today?

Prescient’s shares have been on the move since the company reported its FY21 earnings last month.

In its report, the company saw a 6% decrease in revenue from the previous year and increased its loss after tax by 25%.

It also raised a bunch of capital and grew its net assets by almost $10 million year over year as a result.

However, being a clinical stage biotechnology company, Prescient is less concerned with revenue and profits than it is with clinical trial results. So it’s important to hone in on this to get an accurate snapshot of what’s behind the company’s share price.

The company’s lead drug candidates, PTX-100 and PTX-200 have each progressed through initial phase stages of clinical trials and shown positive results.

Both compounds are aimed at the treatment and prevention of cancer, by blocking the growth of tumours in the body.

In its FY21 earnings release, Prescient advised that PTX-100 successfully completed Phase 1b trials in FY21, with the label “yielding encouraging results”.

PTX-200 is currently in a Phase 1b trial investigating its safety and efficacy in patients with a complex condition known as relapsed and refractory acute myeloid leukaemia (AML).

More information concerning the next stages of both candidates is expected over the coming periods.

Aside from this, another key takeout from Prescient’s year in FY21 was the development of its OmniCAR platform.

OmniCAR was created to overcome some of the challenges and limitations of CAR-T treatments – a new type of intervention used in immunotherapy and the treatment of cancer.

The company made significant developments in this area over the course of FY21, marking another step forward in its clinical and growth narratives.

Investors certainly appear to have bought the Prescient Therapeutics share price on this clinical momentum, pushing it 58% higher in the few weeks since the company released its FY21 performance.

Prescient Therapeutics share price snapshot

The Prescient Therapeutics share price has posted a year to date return of 348%, extending its gain over the past 12 months to 341%.

Over the last month alone, it has climbed a further 54% into the green.

Each of these results has far outpaced the broad index’s climb of around 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

a man sits on his sofa loong at his phone and raises a fist to the air in happy celebration.
Resources Shares

Chalice Mining share price leaps 13% on new exploration results

The ASX resource explorer is using small footprint diamond drill rigs to minimise environmental impacts.

Read more »

A man in his 30s holds his computer underneath and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Gainers

Guess which ASX All Ords shares are serving up 15% gains today

Tech shares continue to lead the way on Wednesday.

Read more »

rising asx share price in food and consumer staples sector represented by happy face made from cut up banana
Share Gainers

Why Domino’s, EML, Talga, and Woolworths shares are pushing higher

These ASX shares are pushing higher on Wednesday...

Read more »

A graph ablaze with fire going up, indicating a fired up and surged share price
Share Gainers

These 3 ASX 200 tech shares are on fire today

Tech shares are broadly outperforming today following a strong lead from the US NASDAQ.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Gainers

Why Regis Resources, Sayona, Woodside, and Xero shares are pushing higher

These ASX shares are on form on Tuesday...

Read more »

A GWR Group female employee in a hard hat and overalls with high visibility stripes sits at the wheel of a large mining vehicle with mining equipment in the background.
Resources Shares

Why has the Pilbara Minerals share price soared 57% in FY22?

How did the Pilbara Minerals share price perform in the financial year?

Read more »

A man with a scrappy beard and wearing dark sunglasses and a beanie head covering raises a fist in happy celebration as he sits at is computer in a home environment.
Technology Shares

How Brainchip shares gained 63% in a year when tech stocks nosedived

The computer hardware provider was once considered a meme stock. Is it fair dinkum now?

Read more »

A technical manufacturer checks his work in a high-tech lab with precision equipment in the background.
Share Gainers

Guess which ASX All Ords share soared 21% to an 8-year high on Monday

One ASX All Ordinaries share enjoyed a stellar start to the week.

Read more »